|
From CRP to IL-6 to IL-1: Moving Upstream To Identify Novel Targets for Atheroprotection
|
5
|
Resverlogix Corp.
|
May 11, 2019 04:06PM
|
|
From IR re: Prospectus Offering and Corporate Presentation
|
3
|
Resverlogix Corp.
|
May 23, 2019 03:57PM
|
|
FSHD and apabetalone topical formulation
|
6
|
Resverlogix Corp.
|
Feb 27, 2019 01:36PM
|
|
FSHD- Acceleron’s ACE-083 Therapy Candidate
|
2
|
Resverlogix Corp.
|
May 07, 2018 01:58PM
|
|
FXR and liver transaminase related adverse events
|
7
|
Resverlogix Corp.
|
Sep 18, 2018 11:25PM
|
|
FYI, Zenith update on Thursday 6/18
|
6
|
Resverlogix Corp.
|
Jun 16, 2020 07:20AM
|
|
Gene therapy’s new hope: A neuron-targeting virus is saving infant lives
|
1
|
BIOASIS TECHNOLOGIES INC
|
Nov 04, 2017 01:58PM
|
|
Genentech/Roche BET inhibitor toxicity paper
|
5
|
Resverlogix Corp.
|
Apr 19, 2016 02:46PM
|
|
General360
|
3
|
Resverlogix Corp.
|
Jun 21, 2017 02:59PM
|
|
German drug maker Morphosys to buy Constellation Pharma in $1.7 billion deal
|
8
|
Zenith Epigenetics
|
Jun 03, 2021 10:45AM
|
|
Getting amyloid beta antibodies across the BBB.....
|
4
|
BIOASIS TECHNOLOGIES INC
|
Feb 02, 2018 11:25AM
|
|
Gilead GS-5829 BET inhibitor mCRPC trial
|
4
|
Zenith Epigenetics
|
Oct 01, 2016 09:51PM
|
|
Gilead GS-5829 Perspective
|
4
|
Zenith Epigenetics
|
Jul 20, 2017 12:26PM
|
|
Gilead's GS-5829 flops in mCRPC
|
10
|
Zenith Epigenetics
|
Jul 13, 2022 11:03AM
|
|
Going on 5 months since database lock....
|
5
|
Resverlogix Corp.
|
Feb 13, 2020 07:01AM
|
|
Going up.....The elevator has left the basement
|
|
BIOASIS TECHNOLOGIES INC
|
Apr 25, 2017 04:23PM
|
|
Goodbye March, Hello April
|
2
|
Resverlogix Corp.
|
Mar 22, 2019 06:52PM
|
|
Goodbye Q3, Hello Q4. RVX in the Next 2 Weeks.
|
7
|
Resverlogix Corp.
|
Sep 28, 2016 09:36AM
|
|
Gordon Research Conference
|
7
|
Resverlogix Corp.
|
May 29, 2019 02:47PM
|
|
Gordon Research Conference Presentation Thursday June 14th
|
11
|
Resverlogix Corp.
|
Jun 12, 2018 12:20PM
|
